Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11426380
Urolithins as immune response enhancers
granted -
US 11426393
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11426409
Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
granted -
US 11426414
Pharmaceutical compositions comprising meloxicam
granted -
US 11426420
Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
granted -
US 11426446
Stable aqueous formulations of aflibercept
granted -
US 11426418
Injectable long-acting semi-solid gel formulations
granted -
US 11426464
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
granted -
US 11427540
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11426486
Chitosan-containing formulations
granted -
US 11427581
JAK inhibitor and use thereof
granted -
US 11427605
Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine
granted -
US 11427588
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
granted -
US 11427646
Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
granted -
US 11427816
Cancer treatment through RLIP76 partial depletion
granted -
US 11427820
Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
granted -
US 11427838
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
granted -
US 11426373
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
granted -
US 11426366
Compositions and methods for treating motor disorders
granted -
US 11426461
Methods for preventing dengue and hepatitis A
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11426385
Methods of improving cancer chemotherapy
granted -
US 11426415
Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
granted -
US 11426448
Methods for treatment of erectile dysfunction with sonic hedgehog compounds
granted -
US 11426467
Dosage regimes for the administration of an anti-CD25 ADC
granted -
US 11427634
Human anti-semaphorin 4D antibody
granted -
US 11427644
Dual antigen-induced bipartite functional complementation
granted -
US 11427823
Targeted compositions
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
US 11435349
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
granted -
US 11434505
Universal donor cells
granted -
US 11435366
Noninvasive method to quantify kidney function and functional decline
granted -
US 11433143
Nano-enabled immunotherapy in cancer
granted -
US 11433131
Adoptive cell therapy using spherical nucleic acids (SNAs)
granted -
US 11433091
Methods and compositions for administration of iron
granted -
US 11433038
High concentration medicant solutions for treating neurological disorders
granted -
US 11433025
Oil foamable carriers and formulations
granted -
US 11432547
Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same
granted -
US 11433013
Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof
granted -
US 11433029
Formulation of an antibody and use thereof
granted -
US 11433035
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted -
US 11433057
Method for improving or enhancing cognition
granted -
US 11433078
Pharmaceutical compositions comprising meloxicam
granted -
US 11433079
Pharmaceutical compositions comprising meloxicam
granted -
US 11433053
LSD1 inhibitor and preparation method and application thereof
granted -
US 11434502
Treatment of amyotrophic lateral sclerosis (ALS)
granted -
US 11434293
Anti TRBC1 antigen binding domains
granted -
US 11434272
Anti-human papillomavirus 16 E7 T cell receptors
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.